Sudo Biosciences has begun a Phase I trial of SUDO-550, a drug candidate designed to treat neuroinflammatory diseases.

Reporting in Nature, Gray and colleagues identify and characterize a selective allosteric inhibitor of BCR–ABL, GNF-5, that cooperates with ATP competitive inhibitors to inhibit both wild-type ...

WNKs sense osmotic pressure by binding specific water molecules to the inactive dimeric configuration of WNK1 and WNK3, integrating signals with chloride inhibition as demonstrated by mutagenesis and ...